Phase III Adaptive Adaptive Stereostactic Body Radiotherapy (SBRT) With Dose Escalation for High-Risk Prostate Cancer

The aim of this clinical trial is to evaluate the efficacy of adaptive prostate Stereotatic Body RadioTherapy (SBRT), which integrates both Whole Pelvic RadioTherapy (WPRT) and dose escalation on the Dominant Intraprostatic Lesion (DIL), compared with standard radiotherapy. This will be assessed using a 5-year cost-utility analysis based on data from the clinical trial and the National Health Data System (NHDS).

Trial Details

NCT ID
NCT07189598
Phase
NA
Sponsor
Center Eugene Marquis
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Adaptive Stereostatic Body RadioTherapy (SBRT) including both Whole Pelvic RadioTherapy (WPRT) and dose-escalation on the Dominant Intraprostatic Lesion (DIL)
  • conventional or a moderately hypofractionated
Locations (sample)
  • Rennes, France|48.11109,-1.67431

Key Eligibility Criteria

  • Age ≥ 18 years
  • ECOG (Eastern Cooperative Oncology Group) performance status 0-2
  • Histologically proven prostate adenocarcinoma, not previously treated
  • High-risk or very high-risk according to the National Comprehensive Cancer Network (NCCN) :

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →